Speakers - Sachs Associates

More documents

Recommendations

Info

CONTACT Dr Arin Ghasparian Chief Executive Officer ADDRESS Virometix AG Winterthurerstrasse 190 8057 Zurich Switzerland TELEPHONE +41 44 63 56117 FAX +41 44 63 56833 EMAIL arin.ghasparian@virometix.com YEAR FOUNDED 2006 Virometix AG www.virometix.com COMPANY PROFILE Virometix is a privately held young innovative Swiss Biotech company developing a new class of vaccines, which should overcome limitations of current biological vaccines in terms of safety, efficacy, speed, stability and manufacturing cost. Virometix Synthetic Virus-Like Nanoparticle (SVLP) technology platform offers the following value propositions: Safety. Virometix SVLP-based vaccines avoid the use of life pathogens and the safety concerns associated with the biological manufacturing processes used for conventional vaccines. Quality. SVLPs are based on a proprietary lipopeptide self-assembly process that leads to atomically defined nanoparticles with a constant size and number of lipopeptide monomers per particle, which increases the specificity and quality of the elicited immune response and assures lot-to-lot consistency. Efficacy. SVLPs efficiently deliver antigens to antigen presenting cells for optimal B- and T-cell responses and induce antibodies that bind with very high affinity to the native target antigen. Convenience. SVLPs do not require sonication, refolding, extrusion or similar processes. SVLPs can be prepared by simply dissolving freeze-dried lipopeptide monomers in a buffer suitable for injection shortly before use. Virometix develops vaccines for infectious diseases and cancer. Two vaccines are in early preclinical development. Virometix offers collaborative research and licensing partnerships for selected vaccines and disease areas. MANAGEMENT Arin Ghasparian, CEO and co-founder John A. Robinson, CSO and co-founder t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
CONTACTS Dr Sonja Reingruber Chief Executive Officer Prof Dr Peter Petzelbauer (CSO) Chief Scientific Officer ADDRESS Xiber Science GmbH Perlhofgasse 2/1 2372 Giesshuebl Austria TELEPHONE +43 699 170 54086 Prof Dr Peter Petzelbauer (CSO) +43 699 170 54087 EMAIL s.reingruber@xiberscience.com peter.petzelbauer @meduniwien.ac.at YEAR FOUNDED December 2009 Xiber Science www.xiberscience.com FINANCIAL SUMMARY Financial need: ~ 4 Mio € Shareholder Investment: 100 k € Public grants approved: 570 k € Public grants pending: 1,3 Mio € LOI over VC–investment: 1 Mio € COMPANY PROFILE Xiber is a biopharmaceutical start–up company. Xiber develops new peptide drugs to improve outcome of critical care & transplant patients. Xiber’s peptide drugs preserve organ function & prevent Organ failure. Xiber will enter market by two niche indications: Acute Lung Injury & Lung Transplantation – with a total market volume of 630 Mio. USD. In 2015 Xiber will complete the preclinical development for both indications. A phase I clinical trial will start with the beginning of 2016. Xiber’ developmental program is driven by a small core team of highly qualified executives, supported by network of academic collaborators and contract research partners in a virtual development environment. After completion of the phase I trial Xiber aims to partner with an appropriate Pharma or Biotech company. Xiber is a spin-off of the Medical University of Vienna. The majority of the shares is owned by the founders S. Reingruber & P. Petzelbauer. The University holds a non-controlling interest and rewards its shares by providing cooperation, infrastructure, facility services and management support. MANAGEMENT Sonja Reingruber, PhD, CEO Molecular Biologist Certified for Regulatory Affairs & Clinical Trial Management; over 10 years experience in Biotech from start-up to licence deal. Expert for acquisition of public grants & funds Peter Petzelbauer, MD, CSO Prof. of Microvascular Research MedUni Vienna; over 10 years experience in Biotech & translational research; international scientific network, holder of 10 patents Michael Hoffmann, Ms, CFO Business Economist; more than 10 years in Biotech management positions; Expert for early stage financing. t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
Page 1 and 2:
B I O T E C H I N E U R O P E I N V
Page 3 and 4:
Events Diary For regular updates, s
Page 5 and 6:
Speakers Alexey Eliseev, Managing D
Page 7 and 8:
Speakers Blake M. Paterson, Co-Foun
Page 9 and 10:
Speakers David Slack, Head of Corpo
Page 11 and 12:
Speakers Frank Grams, VP, Head Alli
Page 13 and 14:
Speakers Iain Buchanan, CEO, NOXXON
Page 15 and 16:
Speakers Juhani Lahdenperä, CEO, H
Page 17 and 18:
Speakers Marcel Zwaal, CBO, DCPrime
Page 19 and 20:
Speakers Paul Higham, Managing Dire
Page 21 and 22:
Speakers Richard Goodfellow, CEO, S
Page 23 and 24:
Speakers Søren Moller, Managing In
Page 25 and 26:
CONTACT Robert F Burns, PhD Chief E
Page 27 and 28:
CONTACTS Rostislav Raykov Chief Exe
Page 29 and 30:
CONTACTS Vincent Charlon PhD, CEO Z
Page 31 and 32:
CONTACTS Dr Bassam Damaj Chairman,
Page 33 and 34:
CONTACT Carina Schmidt Chief Execut
Page 35 and 36:
CONTACT Mr Richard Godfrey Chief Ex
Page 37 and 38:
CONTACTS Tom Kronbach, PhD Chief Ex
Page 39 and 40:
CONTACTS Andreas Caduff, PhD Chief
Page 41 and 42:
CONTACTS Dr Blake Paterson Co-Found
Page 43 and 44:
CONTACT Wolfgang Kintzel Chief Exec
Page 45 and 46:
CONTACT Mike Romanos PhD Chief Exec
Page 47 and 48:
CONTACT Harry Welten, MBA Chief Fin
Page 49 and 50:
CONTACT Barbara Stiefel Office Mana
Page 51 and 52: CONTACTS Ana Martinez Assistant Jua
Page 53 and 54: CONTACTS Dr Rudi D Neirinckx Chief
Page 55 and 56: CONTACT Martin Bonde, PhD, BComm Ch
Page 57 and 58: CONTACT Benedikt Timmerman Chief Ex
Page 59 and 60: CONTACT Malcolm Weir Chief Executiv
Page 61 and 62: CONTACTS Mr Paul Higham Chief Execu
Page 63 and 64: CONTACTS Kevin FitzGerald Chief Ope
Page 65 and 66: CONTACT Roel Q. J Schaapveld, PhD,
Page 67 and 68: CONTACT Maaike Vogelezang Managemen
Page 69 and 70: CONTACT Tom Johnston Chief Executiv
Page 71 and 72: CONTACTS Aaron Powers President Dav
Page 73 and 74: CONTACTS General and Media Contact
Page 75 and 76: CONTACTS Martin Welschof Chief Exec
Page 77 and 78: CONTACTS Carlos Buesa Chief Executi
Page 79 and 80: CONTACTS Nick McCooke Chief Executi
Page 81 and 82: CONTACT Dr Erik Buntinx Chief Execu
Page 83 and 84: CONTACT Michael Altorfer, Ph.D. Hea
Page 85 and 86: CONTACT Matthew B. Lehman Chief Ope
Page 87 and 88: ADDRESS Otto-Hahn-Strasse 15 D- 442
Page 89 and 90: CONTACT Dr Roman Schenk Chief Execu
Page 91 and 92: CONTACTS Dr Hans Fliri Chairman Sim
Page 93 and 94: CONTACTS Dr Raúl Insa Chief Execut
Page 95 and 96: CONTACT Dr Johanna Holldack, MD Chi
Page 97 and 98: CONTACT Eduardo Bravo (speaker) Man
Page 99 and 100: CONTACTS Piers Morgan Chief Financi
Page 101: CONTACT Jakob Knudsen Chief Executi
Page 105 and 106: Supporting Organisations Citigate D
Page 107 and 108: Supporting Organisations Life Scien
Page 109 and 110: Supporting Organisations Swiss Biot
Page 111 and 112: Supporting Organisations Torreya Pa
Page 113: B I O T E C H I N E U R O P E I N V
show all

Speakers - Sachs Associates

Create successful ePaper yourself

Delete template?

Save as template?